Results 91 to 100 of about 8,933 (160)

Use of oral anticoagulants after intramedullary nailing of femur and tibial fractures in trauma department

Travmatologiâ i Ortopediâ Rossii, 2016
The authors evaluated of the effectiveness of new oral anticoagulants in patients with diaphyseal fractures of the femur and tibia.We analyzed the effectiveness of thromboprophylaxis in 85 patients with diaphyseal fractures of the femur and tibia in the ...
A. K. Dulaev, A. N. Tsed, I. G. Dzhusoev
doaj  

Possibilities for monitoring the pharmacodynamics of dabigatran etexilate

Якутский медицинский журнал
The sensitivity and prognostic value of laboratory tests and methods for assessing pharmacodynamics in relation to the system of regulation of the aggregate state of blood after a single dose of dabigatran etexilate at a dosage of 150 mg were ...
M. A. Solovyev, D. A. Momot, L. Y. Kotlovskaya, I. I. Tyutrin, V. V. Udut   +4 more
doaj   +1 more source

Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2021
Farhan N, Cristofoletti R, Basu S, Kim S, Lingineni K, Jiang S, Brown JD, Fang LL, Lesko LJ, Schmidt S.   +9 more
europepmc   +1 more source

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation:a prospective nationwide cohort study

, 2013
The aim of this study was to assess the efficacy and safety in an "everyday clinical practice" population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran etexilate after its post-approval availability in Denmark ...
Due, Karen Margrete, Larsen, Torben Bjerregaard, Callréus, Torbjörn, Rasmussen, Lars Hvilsted, Rosenzweig, Mary, Skjøth, Flemming, Lip, Gregory Y H   +6 more
core   +1 more source

Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. [PDF]

J Thromb Haemost, 2021
Röshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell LG, Bergstrand M, Ibrahim MMA, Joseph D, Tartakovsky I, Gropper S, Brueckmann M, Brandão LR.   +14 more
europepmc   +1 more source

Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial. [PDF]

Medicine (Baltimore), 2021
Song R, Qu R, Wang Y, Zhou D, Zhang A.
europepmc   +1 more source

Case Report Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease

, 2020
Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Mrinal Yadava, Heather S Laird-Fick, Venu Gourineni, Joonseok Kim, In Chul An, George S Abela, Abrar Sayeed   +6 more
core  

UV SPECTROPHOTOMETRIC ASSAY METHOD DEVELOPMENT AND VALIDATION OF DABIGATRAN ETEXILATE IN CAPSULES [PDF]

, 2015
Objective: To develop a simple and a cheap UV spectrophotometric method for the quantitative estimation of Dabigatran etexilate in capsules and validate as per ICH guidelines.Methods: The optimized method uses triethyl ammonium phosphate aqueous solution
Kumar, A. Ashok, Bhavani, G., Hussain, Syed Shahed   +2 more
core   +1 more source

Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate

, 2010
Patients with atrial fibrillation at moderate to high risk of stroke are not always anticoagulated despite a lack of contraindications to vitamin K antagonists (VKAs) like warfarin. These patients are treated with aspirin, aspirin-clopidogrel combination
Gregory Y. H. Lip, Neil S. Roskell, Plumb, JM, Jonathan M. Plumb, Roskell, NS, Lip, Gregory, Noack, H, Clemens, A, Herbert Noack, Andreas Clemens   +9 more
core   +1 more source

Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. [PDF]

J Thromb Haemost, 2021
van Gorp RH, Dijkgraaf I, Bröker V, Bauwens M, Leenders P, Jennen D, Dweck MR, Bucerius J, Briedé JJ, van Ryn J, Brandenburg V, Mottaghy F, Spronk HMH, Reutelingsperger CP, Schurgers LJ.   +14 more
europepmc   +1 more source